Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis.

Williams, Cayman; Kennedy, Alan; Robinson, Maximillian A; Lloyd, Christopher; Dovedi, Simon J; Sansom, David M

Williams, Cayman; Kennedy, Alan; Robinson, Maximillian A; Lloyd, Christopher; Dovedi, Simon J; Sansom, David M.

Afiliação

Williams C; University College London (UCL) Institute of Immunity and Transplantation, London, United Kingdom.
Kennedy A; University College London (UCL) Institute of Immunity and Transplantation, London, United Kingdom.
Robinson MA; University College London (UCL) Institute of Immunity and Transplantation, London, United Kingdom.
Lloyd C; Biologics Engineering, R&D, AstraZeneca, Cambridge, United Kingdom.
Dovedi SJ; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
Sansom DM; University College London (UCL) Institute of Immunity and Transplantation, London, United Kingdom.

Front Immunol ; 13: 871802, 2022.

Article em En | MEDLINE | ID: mdl-36119113

Assuntos

Antígeno B7-1; Comunicação Celular; Abatacepte; Antígeno B7-1/metabolismo; Ipilimumab/farmacologia; Ipilimumab/uso terapêutico; Ligantes

Palavras-chave

CTLA4; anti-CTLA4; checkpoint blockade; ipilimumab; transendocytosis; tremelimumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Comunicação Celular / Antígeno B7-1 Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google